In a specialized breakout session from the 2022 Targeted Therapies Forum, Dr. Nagashree Seetharamu delves deep into the world of NTRK+ NSCLC treatment. Learn the intricacies of two promising medications, Larotrectinib & Entrectinib, that are setting new benchmarks in the realm of non-small cell lung cancer therapies.
Special thanks to our committed sponsors for their continual support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech.
For cutting-edge insights and groundbreaking discoveries in oncology, ensure to visit http://cancerGRACE.org/. Engage with a community of experts and fellow enthusiasts by joining the conversation at https://cancergrace.org/forum.